147 related articles for article (PubMed ID: 29766362)
1. Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
Blok EJ; Engels CC; Dekker-Ensink G; Meershoek-Klein Kranenbarg E; Putter H; Smit VTHBM; Liefers GJ; Morden JP; Bliss JM; Coombes RC; Bartlett JMS; Kroep JR; van de Velde CJH; Kuppen PJK
Breast Cancer Res Treat; 2018 Aug; 171(1):65-74. PubMed ID: 29766362
[TBL] [Abstract][Full Text] [Related]
2. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
5. Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial.
Roseweir AK; Bennett L; Dickson A; Cheng K; Quintayo MA; Bayani J; McMillan DC; Horgan PG; van de Velde CJH; Seynaeve C; Hasenburg A; Kieback DG; Markopoulos C; Dirix LY; Rea DW; Mallon EA; Bartlett JMS; Edwards J
J Natl Cancer Inst; 2018 Jun; 110(6):616-627. PubMed ID: 29917140
[TBL] [Abstract][Full Text] [Related]
6. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
[TBL] [Abstract][Full Text] [Related]
7. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
Derks MGM; Blok EJ; Seynaeve C; Nortier JWR; Kranenbarg EM; Liefers GJ; Putter H; Kroep JR; Rea D; Hasenburg A; Markopoulos C; Paridaens R; Smeets JBE; Dirix LY; van de Velde CJH
Lancet Oncol; 2017 Sep; 18(9):1211-1220. PubMed ID: 28732650
[TBL] [Abstract][Full Text] [Related]
9. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
Dieci MV; Conte P; Bisagni G; Brandes AA; Frassoldati A; Cavanna L; Musolino A; Giotta F; Rimanti A; Garrone O; Bertone E; Cagossi K; Sarti S; Ferro A; Piacentini F; Maiorana A; Orvieto E; Sanders M; Miglietta F; Balduzzi S; D'Amico R; Guarneri V
Ann Oncol; 2019 Mar; 30(3):418-423. PubMed ID: 30657852
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of T lymphocytes infiltration in breast cancer].
Yu HM; Jiao SC; Yang JL; Wang JD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):199-206. PubMed ID: 23643010
[TBL] [Abstract][Full Text] [Related]
11. Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.
Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
Sci Rep; 2019 Feb; 9(1):1583. PubMed ID: 30733496
[TBL] [Abstract][Full Text] [Related]
12. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
13. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
Gao ZH; Li CX; Liu M; Jiang JY
BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
15. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
[TBL] [Abstract][Full Text] [Related]
16. The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.
Engels CC; Charehbili A; van de Velde CJ; Bastiaannet E; Sajet A; Putter H; van Vliet EA; van Vlierberghe RL; Smit VT; Bartlett JM; Seynaeve C; Liefers GJ; Kuppen PJ
Breast Cancer Res Treat; 2015 Feb; 149(3):587-96. PubMed ID: 25616355
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer.
Lu J; Xu Y; Wu Y; Huang XY; Xie JW; Wang JB; Lin JX; Li P; Zheng CH; Huang AM; Huang CM
BMC Cancer; 2019 Sep; 19(1):920. PubMed ID: 31521128
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy.
Tsiatas M; Kalogeras KT; Manousou K; Wirtz RM; Gogas H; Veltrup E; Zagouri F; Lazaridis G; Koutras A; Christodoulou C; Pentheroudakis G; Petraki C; Bafaloukos D; Pectasides D; Kosmidis P; Samantas E; Karanikiotis C; Papakostas P; Dimopoulos MA; Fountzilas G
Cancer Med; 2018 Oct; 7(10):5066-5082. PubMed ID: 30240146
[TBL] [Abstract][Full Text] [Related]
19. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
